Xencor Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Xencor stock.
View analyst ratings for Xencor or view top-rated stocks.

Wall Street analysts have given Xencor a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Xencor wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Xencor is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Xencor.

Xencor, Inc. (NASDAQ:XNCR) announced its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of ($0.61) by $1.48. Xencor had a net margin of 13.17% and a trailing twelve-month return on equity of 3.97%.
View Xencor's earnings history.

Xencor's stock was trading at $28.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, XNCR shares have increased by 20.3% and is now trading at $33.82.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued 1 year price objectives for Xencor's stock. Their forecasts range from $34.00 to $59.00. On average, they anticipate Xencor's stock price to reach $51.17 in the next twelve months. This suggests a possible upside of 51.3% from the stock's current price.
View analysts' price targets for Xencor or view top-rated stocks among Wall Street analysts.

6 employees have rated Xencor CEO Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among Xencor's employees.

Some companies that are related to Xencor include BridgeBio Pharma (BBIO), Sarepta Therapeutics (SRPT), Mawson Infrastructure Group (WIZP), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), Legend Biotech (LEGN), Blueprint Medicines (BPMC), Perrigo (PRGO), Allakos (ALLK), I-Mab (IMAB), Cerevel Therapeutics (CERE), Ionis Pharmaceuticals (IONS), Alkermes (ALKS) and Arvinas (ARVN).
View all of XNCR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Xencor's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.75%), FMR LLC (14.17%), Vanguard Group Inc. (10.85%), Price T Rowe Associates Inc. MD (10.05%), Primecap Management Co. CA (9.08%) and State Street Corp (4.47%). Company insiders that own Xencor stock include Bassil I Dahiyat, Celia Eckert, John J Kuch, John S Stafford III and Ronin Capital, Llc.
View institutional ownership trends for Xencor.

XNCR stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., FMR LLC, Squarepoint Ops LLC, California Public Employees Retirement System, SG Americas Securities LLC, Northern Trust Corp, and Legal & General Group Plc. Company insiders that have sold Xencor company stock in the last year include Bassil I Dahiyat, Celia Eckert, and John J Kuch.
View insider buying and selling activity for Xencor or view top insider-selling stocks.

XNCR stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Price T Rowe Associates Inc. MD, Rhenman & Partners Asset Management AB, Vanguard Group Inc., Citadel Advisors LLC, Millennium Management LLC, Renaissance Technologies LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Xencor or or view top insider-buying stocks.

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XNCR stock can currently be purchased for approximately $33.82.

Xencor has a market capitalization of $1.97 billion and generates $122.69 million in revenue each year. The biopharmaceutical company earns $-69,330,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

Xencor employs 202 workers across the globe.

The official website for Xencor is www.xencor.com.

Xencor is headquartered at 111 WEST LEMON AVENUE, MONROVIA CA, 91016.

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at (626) 305-5900 or via email at [email protected].